SCHEMBL5658580

SCHEMBL5658580

Cc1cc(C2(c3cc(C)c(O)c(C)c3)C(=O)N(Cc3ccccc3Cl)c3ccccc32)cc(C)c1N

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 7/20 0.48
ALDH1A1 P00352 6/20 0.48
TSHR P16473 3/20 0.48
HSD17B10 Q99714 2/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
HTT P42858 2/20 0.48
LMNA P02545 2/20 0.48
ALOX15 P16050 1/20 0.48
MAPT P10636 7/20 0.46
POLB P06746 2/20 0.46
NPSR1 Q6W5P4 1/20 0.46
CNR1 P21554 1/20 0.43
GPR55 Q9Y2T6 1/20 0.43
EDNRB P24530 1/20 0.39
EDNRA P25101 1/20 0.39
P2RX7 Q99572 1/20 0.39
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2C9 P11712 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5659726 0.95 TP53 (0.52) TP53ALDH1A1TSHRHSD17B10SMN1; SMN2
SCHEMBL5658562 0.92 CNR1 (0.47) TP53ALDH1A1TSHRHSD17B10SMN1; SMN2
SCHEMBL5660174 0.90 CNR1 (0.57) TP53ALDH1A1TSHRHSD17B10SMN1; SMN2
SCHEMBL5659749 0.88 MAPT (0.51) TP53ALDH1A1TSHRHSD17B10SMN1; SMN2
SCHEMBL5661002 0.88 TP53 (0.45) TP53ALDH1A1TSHRHSD17B10SMN1; SMN2
SCHEMBL5658782 0.85 TP53 (0.44) TP53ALDH1A1TSHRHSD17B10SMN1; SMN2
SCHEMBL5659557 0.84 TP53 (0.45) TP53ALDH1A1TSHRHSD17B10SMN1; SMN2
SCHEMBL14457600 0.84 MAPT (0.44) TP53ALDH1A1TSHRHSD17B10SMN1; SMN2
SCHEMBL5659627 0.84 TP53 (0.45) TP53ALDH1A1TSHRHSD17B10SMN1; SMN2
SCHEMBL5661435 0.84 TP53 (0.43) TP53ALDH1A1TSHRHSD17B10SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7250442-B2 Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators ELI LILLY AND COMPANY (US) 2007-07-31 US disclosed
US-7250442-B2 Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators ELI LILLY AND COMPANY (US) 2007-07-31 US disclosed
US-7250442-B2 Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators ELI LILLY AND COMPANY (US) 2007-07-31 US disclosed
US-20050054712-A1 Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators ELI LILLY AND COMPANY 2005-03-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050054712-A1 Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators NR3C2, NR5A1, NR5A2 TP53 3370/4885ALDH1A1 723/4885TSHR 341/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.